Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bioventus's gross profit for the
three
months ended in Jun. 2026 was $105.7 Mil. Bioventus's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was $399.4 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Bioventus's gross profit for the
three
months ended in Jun. 2026 was $105.7 Mil. Bioventus's Revenue for the
three
months ended in Jun. 2026 was $153.2 Mil. Therefore, Bioventus's Gross Margin % for the quarter that ended in Jun. 2026 was 68.97%.
Bioventus had a gross margin of 68.97% for the quarter that ended in Jun. 2026 => Durable competitive advantage
During the past 11 years, the highestGross Margin % of Bioventus was 73.63%. The lowest was 64.06%. And the median was 69.77%.
Warning Sign:
Bioventus Inc gross margin has been in long-term decline. The average rate of decline per year is -1.2%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Bioventus had a gross margin of 68.97% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Bioventus Gross Profit Related Terms
Bioventus Gross Profit Historical Data
* Premium members only.
The historical data trend for Bioventus's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Bioventus's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioventus Gross Profit vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bioventus's Gross Profit distribution charts can be found below:
* The bar in red indicates where Bioventus's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $399.4 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Bioventus (BVS) has a Gross Profit of $399.4 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Bioventus and its competitors.
Is Bioventus' Gross Profit too high?
Bioventus' current Gross Profit is $399.4 Mil. Overall, Bioventus has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bioventus' Gross Profit compare to PRCT and IRMD?
Bioventus' Gross Profit of $399.4 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Devices & Instruments company?
A good Gross Profit depends on the Medical Devices & Instruments industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Bioventus and its competitors. Bioventus's current Gross Profit is $399.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioventus stock overvalued right now?
Based on GuruFocus' analysis, Bioventus (BVS) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.26, compared to a current price of $13.56 — trading 86.8% above its estimated fair value. The current Gross Profit is $399.4 Mil. Bioventus' overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Bioventus (BVS), the current Gross Profit is $399.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioventus (BVS) Overvalued in 2026?
Based on GuruFocus' analysis, Bioventus stock appears to be overvalued.
The current stock price of $13.56 is trading 86.8% above its estimated GF Value™ of $7.26.
GuruFocus considers Bioventus to be Significantly Overvalued.
Key valuation signals for BVS:
Gross Profit: $399.4 Mil
GF Value™: $7.26 vs. price of $13.56 (86.8% above fair value)
No single metric tells the full story. See the BVS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
58GF Score
Get the complete analysis for BVS
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BVS has been successfully added to your 
